Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2023 · 12 citations · 27 references
MedicineNeurologyPsychologyCognitive PsychologyDementiaNeuropsychologyAlzheimer DiseaseCognitive AssessmentCognitive ImpairmentCognitive SymptomsDementia BiomarkersDementia Risk FactorsAlzheimer Disease DementiaBiomarkersCognitive BiomarkersCognitive PhenotypesCognitive Status AssessmentElderly PopulationLogistic RegressionPlasma Protein Biomarkers
Introduction: This study investigates whether plasma biomarkers (Aβ42/40 and p-tau 181), APS, as well as apolipoprotein E (APOE) proteotype predict cognitive deficits in elderly adults from the Democratic Republic of Congo. Methods: Forty-four with possible AD (pAD) and 41 healthy control (HC) subjects were screened using CSID and AQ, underwent cognitive assessment with the African Neuropsychology Battery (ANB), and provided blood samples for plasma Aβ42, Aβ40, Aβ42/40, and APOE proteotype. Linear and logistic regression were used to evaluate the associations of plasma biomarkers with ANB tests and the ability of biomarkers to predict cognitive status. Results: Patients with pAD had significantly lower plasma Aβ42/40 levels, higher APS, and higher prevalence of APOE E4 allele compared to HC. Groups did not differ in levels of Aβ40, Aβ42, or P-tau 181. Results showed that Aβ42/40 ratio and APS were significantly associated with African Naming Test (ANT), African List Memory Test (ALMT), and African Visuospatial Memory Test (AVMT) scores, while the presence of APOE E4 allele was associated with ANT, ALMT, AVMT, and APT scores. P-tau 181 did not show any significant associations while adjusting for age, education, and gender. APS showed the highest area under the curve (AUC) value (AUC = 0.78, 95% confidence interval [CI]: 0.68-0.88) followed by Aβ42/40 (AUC = 0.75, 95% CI: 0.66-0.86) and APOE E4 (AUC = 0.69 (CI 0.57-0.81) in discriminating pAD from HC. Discussion: These results demonstrate associations between select plasma biomarker of AD pathology (Aβ42/40), APS, and APOE E4 allele) and ANB test scores and the ability of these biomarkers to differentiate pAD from cognitively normal SSA individuals, consistent with findings reported in other settings.
27
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Akinori Nakamura, Naoki Kaneko, Victor L. Villemagne et al. · Nature · 2018 · 1.7K citations · Full text
Thomas K. Karikari, Tharick A. Pascoal, Nicholas J. Ashton et al. · The Lancet Neurology · 2020 · 1.4K citations · Full text
Shorena Janelidze, Niklas Mattsson, Sebastian Palmqvist et al. · Nature Medicine · 2020 · 1.3K citations
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology
Claire Bridel, Wessel N. van Wieringen, Henrik Zetterberg et al. · JAMA Neurology · 2019 · 760 citations · Full text